These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19039126)

  • 1. Microbiology. An antibiotic mimics immunity.
    Nathan C
    Science; 2008 Nov; 322(5906):1337-8. PubMed ID: 19039126
    [No Abstract]   [Full Text] [Related]  

  • 2. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.
    Singh R; Manjunatha U; Boshoff HI; Ha YH; Niyomrattanakit P; Ledwidge R; Dowd CS; Lee IY; Kim P; Zhang L; Kang S; Keller TH; Jiricek J; Barry CE
    Science; 2008 Nov; 322(5906):1392-5. PubMed ID: 19039139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coenzyme F
    Purwantini E; Loganathan U; Mukhopadhyay B
    J Bacteriol; 2018 Dec; 200(23):. PubMed ID: 30249701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor.
    Somasundaram S; Anand RS; Venkatesan P; Paramasivan CN
    BMC Microbiol; 2013 Oct; 13():218. PubMed ID: 24083570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecule Property Analyses of Active Compounds for
    Makarov V; Salina E; Reynolds RC; Kyaw Zin PP; Ekins S
    J Med Chem; 2020 Sep; 63(17):8917-8955. PubMed ID: 32259446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximizing bactericidal activity with combinations of bioreduced drugs.
    Goldman RC
    Future Med Chem; 2010 Aug; 2(8):1253-71. PubMed ID: 21426017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).
    Cherian J; Choi I; Nayyar A; Manjunatha UH; Mukherjee T; Lee YS; Boshoff HI; Singh R; Ha YH; Goodwin M; Lakshminarayana SB; Niyomrattanakit P; Jiricek J; Ravindran S; Dick T; Keller TH; Dartois V; Barry CE
    J Med Chem; 2011 Aug; 54(16):5639-59. PubMed ID: 21755942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multistress Model for High Throughput Screening Against Nonreplicating Mycobacterium tuberculosis.
    Gold B; Warrier T; Nathan C
    Methods Mol Biol; 2021; 2314():611-635. PubMed ID: 34235673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.
    Gurumurthy M; Mukherjee T; Dowd CS; Singh R; Niyomrattanakit P; Tay JA; Nayyar A; Lee YS; Cherian J; Boshoff HI; Dick T; Barry CE; Manjunatha UH
    FEBS J; 2012 Jan; 279(1):113-25. PubMed ID: 22023140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.
    Fujiwara M; Kawasaki M; Hariguchi N; Liu Y; Matsumoto M
    Tuberculosis (Edinb); 2018 Jan; 108():186-194. PubMed ID: 29523322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel proteasome inhibitors as potential drugs to combat tuberculosis.
    Cheng Y; Pieters J
    J Mol Cell Biol; 2010 Aug; 2(4):173-5. PubMed ID: 20123700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospects for design of novel antituberculosis drugs].
    Nikitin AV
    Antibiot Khimioter; 2006; 51(9-10):56-60. PubMed ID: 18030793
    [No Abstract]   [Full Text] [Related]  

  • 13. Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles.
    Kim P; Zhang L; Manjunatha UH; Singh R; Patel S; Jiricek J; Keller TH; Boshoff HI; Barry CE; Dowd CS
    J Med Chem; 2009 Mar; 52(5):1317-28. PubMed ID: 19209889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies.
    Denny WA; Palmer BD
    Future Med Chem; 2010 Aug; 2(8):1295-304. PubMed ID: 21426020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-((3,5-Dinitrobenzyl)thio)quinazolinones: Potent Antimycobacterial Agents Activated by Deazaflavin (F
    Jian Y; Forbes HE; Hulpia F; Risseeuw MDP; Caljon G; Munier-Lehmann H; Boshoff HIM; Van Calenbergh S
    J Med Chem; 2021 Jan; 64(1):440-457. PubMed ID: 33347317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PA-824.
    Tuberculosis (Edinb); 2008 Mar; 88(2):134-6. PubMed ID: 18486052
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases.
    Showalter HD
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32927749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Resistance to antitubercular drugs in Chile].
    Valenzuela MT; Scheel G; Ponce J; Lepe R; Velasco M; Valenzuela P
    Rev Med Chil; 1984 Jan; 112(1):76-80. PubMed ID: 6429808
    [No Abstract]   [Full Text] [Related]  

  • 20. A new TB drug by 2010--or sooner?
    Crabb C
    Bull World Health Organ; 2002; 80(6):518-9. PubMed ID: 12132015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.